[
    [
        {
            "time": "",
            "original_text": "西部证券维持贝达药业买入评级，2021年三季报点评：埃克替尼稳定增长，恩沙替尼放量待推进",
            "features": {
                "keywords": [
                    "贝达药业",
                    "买入评级",
                    "2021年三季报",
                    "埃克替尼",
                    "稳定增长",
                    "恩沙替尼",
                    "放量待推进"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券维持贝达药业买入评级，2021年三季报点评：埃克替尼稳定增长，恩沙替尼放量待推进",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]